Browse Results

  • Division: : Cancer Center


There are 218 clinical trial(s) matching your criteria.

Back

CA209436:A Phase I/ II Study to Evaluate the Safety and Preliminary Efficacy of Nivolumab in Combination with Brentuximab Vedotin in Subjects with Relapsed Refractory Non Hodgkin Lymphomas with CD30 Expression CheckMate 436: CHECKpoint pathway and nivolumab clinical Trial Evaluation

Investigator: Alvaro Alencar

Institutional Protocol #: 20170179

National Clinical Trials Identifier: NCT02581631

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: Phase I/II

Enrolling Since: 8/18/2017

A Phase 1, Dose-Finding and Signal-Seeking Study of the Safety and Efficacy of Intravenous CAVATAKTM (coxsackievirus A21, CVA21) Alone and in Combination with Pembrolizumab in Patients with Late Stage Solid Tumours (NSCLC, Castrate-Resistant Prostate Cancer, Melanoma and Bladder Cancer)

Investigator: Jaime Merchan

Institutional Protocol #: 20161016

National Clinical Trials Identifier: NCT02043665

Division: Cancer Center

Therapeutic Area: Prostate, Bladder, and Kidney Cancers

Phase: Phase I

Enrolling Since: 6/16/2017

C-700-01: A Phase 1 / 2, Open-Label, Multiple Ascending Dose Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion to Second-Line Cervical Cancer

Investigator: Breelyn Wilky

Institutional Protocol #: 20170076

National Clinical Trials Identifier: NCT03104699

Division: Cancer Center

Therapeutic Area: Bone and Soft Tissue Cancers

Phase: Phase I/II

Enrolling Since: 4/10/2017

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Entospletinib, a Selective SYK Inhibitor, in Combination with Systemic Corticosteroids as First-Line Therapy in Subjects with Chronic Graft Versus Host Disease (cGVHD)

Investigator: Lazaros Lekakis

Institutional Protocol #: 20160645

National Clinical Trials Identifier: NCT02701634

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: Phase II

Enrolling Since: 2/3/2017

Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) Versus Carfilzomib, Lenalidomide and Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE).

Investigator: James Hoffman

Institutional Protocol #: 20160548

National Clinical Trials Identifier: NCT01863550

Division: Cancer Center

Therapeutic Area: Leukemia, Lymphoma, and Myeloma

Phase: Phase III

Enrolling Since: 12/19/2016

Back